sr141716 has been researched along with Overweight in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (87.50) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noll, G; Périat, D; Sudano, I | 1 |
| Golay, A | 1 |
| Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A | 1 |
| DeSantis, SM; Johansson, K; Neovius, K; Neovius, M; Rössner, S | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Burch, J; Glanville, J; McKenna, C; Norman, G; Palmer, S; Sculpher, M; Woolacott, N | 1 |
| Aguirre, CA; Castillo, VA; Llanos, MN; Ronco, AM; Valenzuela, CA | 1 |
| Ball, MP; Boggs, DL; Buchanan, RW; Conley, RR; Feldman, S; Gorelick, DA; Heishman, SJ; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Warren, KR; Wehring, HJ | 1 |
| Ball, MP; Buchanan, RW; Conley, RR; Feldman, S; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Warren, KR | 1 |
| Després, JP; Golay, A; Sjöström, L | 1 |
| Aronne, LJ; Devin, J; Heshmati, HM; Pi-Sunyer, FX; Rosenstock, J | 1 |
| Majumdar, S; Padwal, R | 1 |
| Després, JP; Golay, A; Hanotin, C; Pi-Sunyer, X; Scheen, AJ; Van Gaal, LG | 1 |
| André, C; Curioni, C | 1 |
| Cleland, SJ; Sattar, N | 1 |
| Finer, N; Hollander, P; Jensen, MD; Scheen, AJ; Van Gaal, LF | 1 |
| Scheen, AJ; Van Gaal, LF | 1 |
| Bray, GA; Ryan, DH | 1 |
| Alemany, M; Cabot, C; Fernández-López, JA; Ferrer-Lorente, R | 1 |
| Saavedra, LE | 1 |
| Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W | 1 |
| McCall, AL | 1 |
| Després, JP; McCarthy, C; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
| Aronne, LJ; Isoldi, KK | 1 |
9 review(s) available for sr141716 and Overweight
| Article | Year |
|---|---|
Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Medication Adherence; Odds Ratio; Orlistat; Overweight; Patient Dropouts; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2009 |
Rimonabant for the treatment of overweight and obese people.
Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2009 |
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Humans; Metabolic Syndrome; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2006 |
Rimonabant for overweight or obesity.
Topics: Adult; Anti-Obesity Agents; Diet, Reducing; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss | 2006 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
Drug treatment of the overweight patient.
Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2007 |
Endocannabinoid system and cardiometabolic risk.
Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
[Obesity in adults].
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss | 2007 |
Overweight and obesity: key components of cardiometabolic risk.
Topics: Adipocytes; Adipokines; Cardiovascular Diseases; Humans; Inflammation; Life Style; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; United States | 2007 |
9 trial(s) available for sr141716 and Overweight
| Article | Year |
|---|---|
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
Topics: Blood Pressure; Body Mass Index; Body Weight; Cardiovascular System; Female; Fenofibrate; Heart; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Time Factors; Waist Circumference | 2008 |
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Schizophrenia; Schizophrenic Psychology | 2011 |
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Body Mass Index; Body Weight; Brain; Cannabinoid Receptor Antagonists; Double-Blind Method; Drug Inverse Agonism; Eating; Energy Intake; Female; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Satiety Response; Schizophrenia; Schizophrenic Psychology; Signal Transduction; Treatment Outcome | 2013 |
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Triglycerides; Weight Loss | 2005 |
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Topics: Adult; Aged; Anti-Obesity Agents; Blood Pressure; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss | 2006 |
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Overweight; Patient Satisfaction; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2006 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
Topics: Appetite Depressants; Cannabinoids; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Obesity; Overweight; Patient Dropouts; Piperidines; Placebos; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss | 2007 |
7 other study(ies) available for sr141716 and Overweight
| Article | Year |
|---|---|
[The endocannabinoid system].
Topics: Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Europe; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
[Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Overweight; Piperidines; Pyrazoles; Rimonabant | 2008 |
The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress.
Topics: Adipose Tissue; Animals; Animals, Newborn; Body Weight; Drug Evaluation, Preclinical; Epididymis; Female; Hormones; Male; Metabolic Diseases; Mice; Overweight; Piperidines; Pregnancy; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological; Time Factors | 2011 |
Metabolic risk factors, drugs, and obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
Does rimonabant pull its weight for type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2006 |
Effects of combined oleoyl-estrone and rimonabant on overweight rats.
Topics: Animals; Anti-Obesity Agents; Appetite; Blood Glucose; Cholecystokinin; Cholesterol; Drug Synergism; Drug Therapy, Combination; Eating; Energy Metabolism; Estrone; Fatty Acids, Nonesterified; Ghrelin; Glucagon-Like Peptide 1; Insulin; Leptin; Male; Obesity; Oleic Acids; Overweight; Peptide Hormones; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Triglycerides | 2007 |
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diet, Reducing; Exercise; Heart Diseases; Humans; Metabolic Diseases; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety | 2008 |